文献速递神经重症与神经感染

法国重型颅脑创伤中颅内压监测联合或不联合脑组织氧分压监测(OXY-TC):一项开放标签、随机对照优效性试验

Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial.
PubMed 文献 · Lancet Neurol · 2023-01-01

在法国25个三级转诊中心,伤后16小时内随机分配318例重型颅脑创伤患者,比较仅颅内压监测与联合脑组织氧分压监测两种策略。主要结局6个月GOSE评分1-4分比例在两组间无显著差异(51% vs 52%;OR 1.0,95%CI 0.6-1.7;P=0.95)。联合监测组导管功能障碍和脑内血肿更常见。

要点

  • 联合脑组织氧分压监测未降低6个月不良神经功能结局比例(51% vs 52%;OR 1.0;P=0.95)。
  • 联合监测组导管功能障碍(8% vs 1%)和导管相关脑内血肿(4% vs 0%)更常见。
  • 两组12个月死亡率无显著差异。

核心结论

  • 重型非穿透性颅脑创伤后,颅内压联合脑组织氧分压监测未减少6个月不良神经功能结局的比例。
  • 联合监测组导管相关技术故障和脑内血肿更常见。
  • 作者认为需进一步研究多模态脑监测的靶向方法是否对特定亚组(如入院时高颅内压)有用。

研究设计与样本

  • 开放标签、随机对照优效性试验,在法国25个三级转诊中心进行。
  • 伤后16小时内随机分配318例18-75岁重型颅脑创伤患者,按年龄和中心分层。
  • 干预为入住ICU前5天内仅颅内压监测(n=160)或颅内压联合脑组织氧分压监测(n=158)。
  • 统计学家和结局评估者设盲;主要分析基于改良意向性治疗人群(仅颅内压组144例,联合监测组147例)。

主要发现

  • 6个月GOSE评分1-4分比例:仅颅内压组51%(95%CI 43-60) vs 联合监测组52%(95%CI 43-60);OR 1.0(95%CI 0.6-1.7);P=0.95。
  • 导管功能障碍:仅颅内压组2/144(1%) vs 联合监测组12/147(8%);P=0.011。
  • 导管相关脑内血肿:仅颅内压组0例 vs 联合监测组6例(4%);P=0.030。
  • 12个月死亡:仅颅内压组33例(脑创伤25例[76%],终末决定6例[18%],脓毒症2例[6%]);联合监测组34例(脑创伤25例[74%],终末决定6例[18%],肺栓塞1例[3%],失血性休克1例[3%],心脏骤停1例[3%]);两组无显著差异。

关键数值与推荐

  • 治疗目标:颅内压维持≤20 mm Hg;联合监测组脑组织氧分压维持>20 mm Hg。
  • 主要结局:伤后6个月GOSE评分1-4分(死亡至重度残疾)的患者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimisation of brain oxygenation might improve neurological outcome after traumatic brain injury. The OXY-TC trial explored the superiority of a strategy combining intracranial pressure and brain tissue oxygen pressure (PbtO2) monitoring over a strategy of intracranial pressure monitoring only to reduce the proportion of patients with poor neurological outcome at 6 months. METHODS: We did an open-label, randomised controlled superiority trial at 25 French tertiary referral centres. Within 16 h of brain injury, patients with severe traumatic brain injury (aged 18-75 years) were randomly assigned via a website to be managed during the first 5 days of admission to the intensive care unit either by intracranial pressure monitoring only or by both intracranial pressure and PbtO2 monitoring. Randomisation was stratified by age and centre. The study was open label due to the visibility of the intervention, but the statisticians and outcome assessors were masked to group allocation. The therapeutic objectives were to maintain intracranial pressure of 20 mm Hg or lower, and to keep PbtO2 (for those in the dual-monitoring group) above 20 mm Hg, at all times. The primary outcome was the proportion of patients with an extended Glasgow Outcome Scale (GOSE) score of 1-4 (death to upper severe disability) at 6 months after injury. The primary analysis was reported in the modified intention-to-treat population, which comprised all randomly assigned patients except those who withdrew consent or had protocol violations. This trial is registered with ClinicalTrials.gov, NCT02754063, and is completed. FINDINGS: Between June 15, 2016, and April 17, 2021, 318 patients were randomly assigned to receive either intracranial pressure monitoring only (n=160) or both intracranial pressure and PbtO2 monitoring (n=158). 27 individuals with protocol violations were not included in the modified intention-to-treat analysis. Thus, the primary outcome was analysed for 144 patients in the intracranial pressure only group and 147 patients in the intracranial pressure and PbtO2 group. Compared with intracranial pressure monitoring only, intracranial pressure and PbtO2 monitoring did not reduce the proportion of patients with GOSE score 1-4 (51% [95% CI 43-60] in the intracranial pressure monitoring only group vs 52% [43-60] in the intracranial pressure and PbtO2 monitoring group; odds ratio 1·0 [95% CI 0·6-1·7]; p=0·95). Two (1%) of 144 participants in the intracranial pressure only group and 12 (8%) of 147 participants in the intracranial pressure and PbtO2 group had catheter dysfunction (p=0.011). Six patients (4%) in the intracranial pressure and PbtO2 group had an intracrebral haematoma related to the catheter, compared with none in the intracranial pressure only group (p=0.030). No significant difference in deaths was found between the two groups at 12 months after injury. At 12 months, 33 deaths had occurred in the intracranial pressure group: 25 (76%) were attributable to the brain trauma, six (18%) were end-of-life decisions, and two (6%) due to sepsis. 34 deaths had occured in the intracranial pressure and PbtO2 group at 12 months: 25 (74%) were attributable to the brain trauma, six (18%) were end-of-life decisions, one (3%) due to pulmonary embolism, one (3%) due to haemorrhagic shock, and one (3%) due to cardiac arrest. INTERPRETATION: After severe non-penetrating traumatic brain injury, intracranial pressure and PbtO2 monitoring did not reduce the proportion of patients with poor neurological outcome at 6 months. Technical failures related to intracerebral catheter and intracerebral haematoma were more frequent in the intracranial pressure and PbtO2 group. Further research is needed to assess whether a targeted approach to multimodal brain monitoring could be useful in subgroups of patients with severe traumatic brain injury-eg, those with high intracranial pressure on admission. FUNDING: The French National Program for Clinical Research, La Fondation des Gueules Cassées, and Integra Lifesciences.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Payen JF, Launey Y, Chabanne R, et al. Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial. Lancet Neurol. 2023. PMID: 37863590. doi:10.1016/S1474-4422(23)00290-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。